ClinicalTrials.gg

Program

cliramitug

Also written as “ALXN2220” and “NI006”.

Its studies are mostly in Amyloidosis, led by 2 companies.

Furthest: phase 3, since Nov 15, 20235 company-led studies, 4 open or runningNext primary completion: Dec 6, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca33 open or runningphase 3since Nov 15, 2023Nov 15, 2023Dec 6, 2027phase 3 · NCT06183931
Neurimmune21 open or runningphase 2since Sep 15, 2025Mar 11, 2020none ahead
  • Named in AstraZeneca’s own pipeline as cliramitug, phase 3, as of Oct 30, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 11, 2020First study: phase 1 study in AmyloidosisNew to NeurimmuneNeurimmune · NCT04360434 · 46 enrolled · France, Germany, Netherlands and more
  2. Nov 15, 2023AstraZeneca's first study: phase 3 study in AmyloidosisNew to AstraZenecaAstraZeneca · NCT06183931 · 1,182 enrolled · United States, Argentina, Australia and more
  3. Sep 15, 2025Phase 2 study in AmyloidosisNeurimmune · NCT07213583 · 35 enrolled · France, Germany, Netherlands and more
  4. May 12, 2026Phase 2 study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)AstraZeneca · NCT07608354 · 326 enrolled · United States, Canada, China and more
  5. Aug 18, 2026Phase 3 study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)AstraZeneca · NCT07789483 · 1,180 planned · United States, Argentina, Australia and more

Ahead

  1. Dec 6, 2027Primary completion: phase 3 study in AmyloidosisAstraZeneca · NCT06183931
  2. Feb 6, 2029Primary completion: phase 2 study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)AstraZeneca · NCT07608354
  3. Jul 11, 2030Primary completion: phase 3 study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)AstraZeneca · NCT07789483

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM) · United States, Argentina, Australia and more3Not yet recruitingAstraZenecaJul 11, 20301,180
NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM) · United States, Canada, China and more2Active, not recruitingAstraZenecaFeb 6, 2029326
NCT07213583Amyloidosis · France, Germany, Netherlands and more2Active, not recruitingNeurimmuneOct 31, 202635
NCT06183931Amyloidosis · United States, Argentina, Australia and more3Active, not recruitingAstraZenecaDec 6, 20271,182
NCT04360434Amyloidosis · France, Germany, Netherlands and more1CompletedNeurimmuneJul 26, 202346

How it is read

Names in the registry

  • “ALXN2220”, 4 entries
  • “NI006”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.